XML 18 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Statements of Cash Flows - USD ($)
 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash flows from operating activities    
Net loss $ (15,757,916) $ (12,882,626)
Adjustments to reconcile net loss to cash used in operating activities    
Stock-based compensation expense 2,241,989 547,109
Depreciation, amortization and accretion 2,263,975 433,471
Issuance of restricted stocks 655,416 0
Amortization of debt issuance costs 0 178,338
Amortization of beneficial conversion feature 0 3,942,613
Derivative (income) expense (212,809) 50,054
Amortization of prepaid research and development - related party (Note 11) 335,454 91,487
Loss on investment 61,519 0
Common stock issued to executives 509,996 0
Issuance of warrants to initial investors 596,434 0
(Gain) on sale of asset (428,374) 0
Warrant amendment 1,507 0
Changes in operating assets and liabilities:    
(Increase) decrease in accounts receivable (180,110) 72,784
Decrease (increase) in inventory 290,984 (581,910)
(Increase) in prepaid expenses and other (126,555) (572,238)
(Decrease) increase in accounts payable and other (307,854) 50,053
(Decrease) in accrued liabilities (146,290) (68,372)
(Decrease) increase in accrued compensation (355,359) 591,451
Increase in interest payable 0 208,941
(Decrease) increase in deferred rent (2,775) 10,560
(Decrease) in deferred revenue 0 (64,286)
Net cash used in operating activities (10,560,768) (7,992,571)
Cash flows used in investing activities    
Deposits 0 1,998
Purchases of fixed assets (53,435) (203,577)
Purchase payment for Natesto asset (6,000,000) 0
Sale of investment in Acerus 1,071,707 0
Sale of investment in Acerus cost (91,864)  
Installment payments for Primsol asset (750,000) (540,000)
Sale of Primsol asset 1,750,000 0
Net cash used in investing activities (4,073,592) (741,579)
Cash flows from financing activities    
Ampio stock subscription payment 0 5,000,000
Sale of stock subscription 0 200,000
Costs related to the conversion of the convertible promissory notes to equity   (29,754)
Proceeds from convertible promissory notes, net 0 5,175,000
Debt issuance costs (Note 8) 0 (298,322)
Issuance of common stock to Lincoln Park Capital 631,481 0
Costs related to sale of common stock (24,247) 0
Warrant tender offer 2,243,281 0
Warrant tender offer cost (332,567) 0
Registered offering costs (997,865) 0
Registered offering of common stock and warrants 8,602,500 0
Over-allotment warrants purchased by placement agents 2,852 0
Net cash provided by financing activities 10,125,435 10,046,924
Net change in cash, cash equivalents and restricted cash (4,508,925) 1,312,774
Cash, cash equivalents and restricted cash at beginning of period 8,054,190 7,353,061
Cash, cash equivalents and restricted cash at end of period 3,545,265 8,665,835
Non-cash transactions:    
Warrant derivative liability related to the issuance of the convertible promissory notes 0 102,931
Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000 0 1,077,000
Conversion of convertible promissory notes and interest of $143,000 to common stock 0 4,268,000
Reclassification of liability based warrants to equity presentation related to the convertible promissory notes 0 87,000
Beneficial conversion feature of $4,943,073 less $3,942,613 of accretion related to unconverted convertible promissory notes 0 1,001,000
Debt issuance costs related to notes that converted to equity 0 (183,000)
Fixed asset purchases included in accounts payable 58,683 0
Warrants issued in connection with the equity financing to the placement agents 292,630 0
Warrants amended in connection with warrant tender offer $ 63,183 $ 0